| Literature DB >> 34248876 |
Xiangning Bai1,2,3,4, Aswathy Narayanan2, Piotr Nowak2,5,6, Shilpa Ray1,6, Ujjwal Neogi1, Anders Sönnerborg1,2,5.
Abstract
Gut microbiome plays a significant role in HIV-1 immunopathogenesis and HIV-1-associated complications. Previous studies have mostly been based on 16S rRNA gene sequencing, which is limited in taxonomic resolution at the genus level and inferred functionality. Herein, we performed a deep shotgun metagenomics study with the aim to obtain a more precise landscape of gut microbiome dysbiosis in HIV-1 infection. A reduced tendency of alpha diversity and significantly higher beta diversity were found in HIV-1-infected individuals on antiretroviral therapy (ART) compared to HIV-1-negative controls. Several species, such as Streptococcus anginosus, Actinomyces odontolyticus, and Rothia mucilaginosa, were significantly enriched in the HIV-1-ART group. Correlations were observed between the degree of immunodeficiency and gut microbiome in terms of microbiota composition and metabolic pathways. Furthermore, microbial shift in HIV-1-infected individuals was found to be associated with changes in microbial virulome and resistome. From the perspective of methodological evaluations, our study showed that different DNA extraction protocols significantly affect the genomic DNA quantity and quality. Moreover, whole metagenome sequencing depth affects critically the recovery of microbial genes, including virulome and resistome, while less than 5 million reads per sample is sufficient for taxonomy profiling in human fecal metagenomic samples. These findings advance our understanding of human gut microbiome and their potential associations with HIV-1 infection. The methodological assessment assists in future study design to accurately assess human gut microbiome.Entities:
Keywords: HIV-1 infection; gut microbiome; resistome; shotgun metagenome sequencing; virulome
Year: 2021 PMID: 34248876 PMCID: PMC8267369 DOI: 10.3389/fmicb.2021.667718
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Characteristics of study subjects.
| Q-C1 | Case | 43 | Male | 440 | 270 | Abacavir/Lamivudine/Dolutegravir | 4.4 | Heterosexual |
| Q-C2 | Case | 48 | Female | 400 | 150 | Abacavir/Lamivudine/Dolutegravir | 8.3 | Heterosexual |
| Q-C3 | Case | 38 | Male | 770 | 344 | Tenofovir (TAF)/Emtricitabine/Rilpivirine | 6.4 | MSM |
| Q-C4 | Case | 42 | Female | 810 | 530 | TDF/Emtricitabine/Rilpivirine | 5.1 | Heterosexual |
| Q-C5 | Case | 43 | Female | 740 | 430 | TDF/Emtricitabine/Dolutegravir | 5.7 | Heterosexual |
| Q-C6 | Case | 54 | Female | 690 | 280 | TDF/Emtricitabine/Efavirenz | 6.8 | Heterosexual |
| Q-C7 | Case | 56 | Female | 800 | 570 | TDF/Emtricitabine/Rilpivirine | 5.0 | Heterosexual |
| Q-C8 | Case | 45 | Male | 680 | 300 | Abacavir/Lamivudine/Dolutegravir | 8.1 | Heterosexual |
| Q-C9 | Case | 62 | Male | 330 | 140 | TAF/Emtricitabine/Dolutegravir | 8.8 | Drug use |
| Q-C10 | Case | 38 | Female | 780 | 300 | Abacavir/Lamivudine/Dolutegravir | 7.7 | Heterosexual |
| Q-D2 | Case | 44 | Female | 1020 | 273 | Dolutegravir/Abacavir/Lamivudine | 20.8 | Heterosexual |
| Q-D3 | Case | 55 | Female | 390 | 170 | TDF/Emtricitabine/Dolutegravir | 20.7 | Blood product |
| Q-D4 | Case | 50 | Female | 970 | 380 | TDF/Emtricitabine/Dolutegravir | 10.9 | Heterosexual |
| Q-H1 | Control | 29 | Male | - | - | - | - | - |
| Q-H2 | Control | 35 | Male | - | - | - | - | - |
| Q-H3 | Control | 51 | Male | - | - | - | - | - |
| Q-H4 | Control | 32 | Male | - | - | - | - | - |
| Q-H5 | Control | 40 | Male | - | - | - | - | - |
| Q-H6 | Control | 24 | Male | - | - | - | - | - |
| Q-H7 | Control | 30 | Male | - | - | - | - | - |
| Q-H8 | Control | 27 | Male | - | - | - | - | - |
| Q-H9 | Control | 42 | Male | - | - | - | - | - |
| Q-H10 | Control | 33 | Male | - | - | - | - | - |
| Q-H11 | Control | 30 | Male | - | - | - | - | - |
FIGURE 1Schematic overview of the study design and workflow. For more details on each step of the workflow, see Materials and Methods.
FIGURE 2Comparison of the quantity and quality of genomic DNA extracted from QIAamp PowerFecal Pro DNA Isolation kit (QP) and IHMS Protocol Q. (A) DNA concentration. (B) 260/280 absorbance ratio. (C) DNA Integrity Number.
FIGURE 3Bacterial composition and difference between HIV-1-antiretroviral therapy (ART) individuals (cases) and HIV-1-negative controls. (A) Taxonomic tree of bacterial taxa identified in this study. Each dot represents a taxonomic entity. From the inner to outer circles, the taxonomic levels range from phylum to species. Different colors of dots indicate different taxonomy levels according to the color key shown. Numbers in parentheses indicate the total number of unique taxonomies at each taxonomic level. (B,C) Barplots of main bacterial taxa at family and genus levels between cases and controls (average abundance >1% in either group). Main taxa at order level are shown in Supplementary Figure 2. (D) Heat map of abundant bacterial species (average abundance >1%) among individuals between cases and controls. The relative abundance of bacterial species is represented by a color gradient as indicated. The species were ordered by decreasing relative abundance. (E) Species biomarkers identified by linear discriminative analysis (LDA) effect size (LEfSe) analysis between cases (in red) and controls (in green). LDA scores (log 10) for the enriched species in controls are represented on the positive scale, while LDA-negative scores indicate enriched species in cases. The threshold used to consider a discriminative feature for the LDA score was set at >2. Taxonomic biomarkers at higher levels are shown in Supplementary Figure 2.
FIGURE 4Alpha and beta diversity of bacterial species between cases and controls. (A) Alpha diversity assessed by observed species richness and Shannon diversity. (B,C) Beta diversity assessed with Bray–Curtis, weighted UniFrac, unweighted UniFrac dissimilarities, as well as non-metric multidimensional scaling (NMDS) based on Bray–Curtis distance. ∗Statistically significant.
FIGURE 5Correlation analysis of gut microbiome and clinical variables. Correlations between clinical variables and bacterial species (A), MetaCyc pathways (B), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (C), virulence factors genes (D), and antimicrobial resistance genes (E). Spearman’s correlation rho values are represented by color gradient as indicated (red is for positive, green is for negative correlation). Only statistically significant correlations (p < 0.05) are shown on the plots.